Richard B. Lanman

Last updated
Dr. Rick Lanman
Dr. Richard B. Lanman 2023-02-08.jpg
Dr. Lanman at his home in 2023
Born
Richard Burnham Lanman Jr.

1955 (age 68–69)
Frankfurt am Main, Hesse, Germany
NationalityAmerican
Education Stanford University, B.S. 1977
Northwestern University School of Medicine, M.D. 1980
Occupation(s) Physician-scientist and Naturalist
Years active1978-present
Known for Biomarkers in Cardiovascular disease and Cancer, and Historical ecology
Relatives Martha Lee Hopkins Struever (mother)
Fritz Lanman (son)
James Lanman (son)
Medical career
Profession Medical Doctor
Institutions Guardant Health, Inc.
Veracyte, Inc.
diaDexus, Inc.
Atherotech, Inc.
San Jose Medical Group, Inc.
Kaiser Permanente
Research Cancer genomics, Precision oncology, Cardiovascular Biomarkers, Thyroid cancer, Interstitial lung disease, Psychiatry, Ecology

Richard Burnham Lanman is an American biotechnology entrepreneur, physician scientist, and naturalist. [1] His contributions relate to improving diagnosis and utilization of less invasive medical procedures, [2] [3] most recently as Global Chief Medical Officer at Guardant Health, Inc., a precision oncology company that developed a blood test replacing invasive tissue biopsies to sequence tumor DNA and improve cancer treatment selection. [4] [5] [6] Lanman has worked in five different medical specialties, oncology, cardiology, endocrinology, pulmonology, and psychiatry, as well as historical ecology, and has authored or co-authored 130 peer-reviewed scientific publications. [7]

Contents

Early life and education

Lanman was born at an U.S. Army Hospital in Frankfurt am Main, Hesse, Germany, in 1955. He is the son of American Indian art dealer and author Martha Lee Hopkins Lanman Struever and Lieutenant Richard Burnham Lanman Sr. [8] Lanman grew up in Munster, Indiana where his parents had a hardware store. At age 11, his father died from leukemia. Lanman graduated Phi Beta Kappa at Stanford University, with a B.S. in Chemistry in 1977.

After obtaining his M.D. from the Northwestern University School of Medicine in 1980, Lanman began his medical internship at Northwestern Memorial Hospital, then in July 1981 began another medical internship at the University of California San Francisco Moffit Hospital. From 1982 to 1985 he completed his residency in psychiatry at Langley Porter Psychiatric Institute, also at UCSF. He became a diplomate of the American Board of Psychiatry and Neurology in 1990. During medical school and residency, Lanman authored journal articles in cardiology and psychiatry, [9] [10] including a book chapter. [11]

Career

Lanman began his medical career as an attending psychiatrist at Kaiser Permanente in Santa Clara County, California in 1985, where he served as Chief of Psychiatry and Chemical Dependency, then, as Chief of Quality. At Kaiser Lanman encouraged adoption of less invasive procedures and improvements in diagnosis in other specialties, culminating in a book chapter he authored on variation in physician practice patterns and hospitalization rates for children with asthma across Kaiser's 14 hospitals in Northern California. [3]

Physician practice management

Lanman left Kaiser Permanente to serve as Chief Medical Officer and Sr. Vice President at San Jose Medical Group (SJMG), in San Jose, California from 1993 to 1995, a large multispecialty physician group practice. [12] [13] [14] [15] San Jose Medical Group was named the "most effective managed care medical group in the country" in 1996 by The Advisory Board Company. [16]

In 1995, Lanman founded Adesso Healthcare Technology Services as Founder and Chief Executive Officer. [17] [18] Adesso offered an alternative to a cost-cutting approach by health maintenance organizations (HMOs) that had been using primary care physicians as gatekeepers, limiting access to specialty physician care. [19] Under Adesso, patients could be referred to specialist physician networks, such as cardiologists or ophthalmologists, without preauthorization. In return the specialist networks contracted directly with health insurers, and instead of fee-for-service, the specialists were reimbursed utilizing severity-adjusted case rates for each episode of care. [2] [20] Adesso filed for an IPO in early 2000, [21] however, the public offering succumbed to the stock market crash that year.

Biotechnology

Lanman transitioned to the biotechnology sector from physician practice management, first joining Atherotech, Inc. as Chief Medical Officer in 2000. Atherotech offered a cardiovascular biomarker diagnostic known as the Vertical Auto Profile- or VAP-expanded cholesterol and lipoprotein test, to improve prediction of risk of heart attack and stroke. [22] [23] [24] [25] [26] There he published validation studies on the VAP test's unique lipoprotein (a) (Lp(a)) cholesterol measurement and other lipoprotein biomarkers. [27] Atherotech was privately acquired by Behrman Capital. [28]

In 2005, Lanman joined a second preventive cardiology biomarker company, diaDexus, Inc., as Executive Vice President and Chief Medical Officer. DiaDexus developed a test for lipoprotein-associated phospholipase A2 (Lp-PLA2), the first FDA-cleared biomarker test to predict risk of stroke. [29] [30] [31] DiaDexus completed a reverse IPO via merger with VaxGen in 2010. [32]

After working in two companies to improve prediction of risk for cardiovascular events, Lanman joined Veracyte, Inc. in 2008 as Chief Medical Officer. Veracyte develops minimally invasive diagnostic tests utilizing genomics. Veracyte's initial genomics tests improved the diagnosis of thyroid nodules and lung nodules without resorting to surgery. [33] [34] Lanman was also principal investigator in a study validating Veracyte's third genomics test to improve diagnosis of idiopathic pulmonary fibrosis versus other idiopathic interstitial pneumonias. [35] Veracyte, Inc. went public in October, 2013. [36]

In September 2014, Lanman joined Guardant Health, Inc. where he served as Global Chief Medical Officer. [6] Guardant's first diagnostic test, Guardant360® enabled sequencing of the DNA in patients' advanced cancers with a simple blood test, as an aid in treatment selection for targeted therapy or immunotherapy without requiring invasive tissue biopsies. [4] This non-invasive test was approved by Medicare to help identify targetable mutations in most solid tumor cancers in 2019. [37] Guardant Health went public in October, 2018. [38]

Historical ecology

Lanman researches and publishes on California's historical ecology to improve and guide efforts at rewilding, often changing understanding of the historical fauna and flora of the state. [39] His first historical ecology discovery was of lost specimens of steelhead trout (Oncorhynchus mykiss) in the collections of the California Academy of Sciences, establishing that in the 1890's the creek behind his house in Los Altos was a trout stream. [40] Next, in a trio of publications, he and colleagues established novel physical evidence that the North American beaver (Castor canadensis) was native to most of California. [41] [42] [43] [1] A fourth publication reported the last record of beaver in the San Francisco Bay Area prior to their extirpation from the fur trade in the form of rock art, known as "Western Message Petroglyphs", which describe a vacant beaver lodge in the Alameda Creek watershed. [44] In 2021, Lanman and colleagues published the results of an ancient DNA sequencing study of salmonid remains from archaeological excavations at Mission Santa Clara which extended the southern limit of the historical spawning range of Chinook salmon, 120 kilometres (75 mi) further south to San Jose, California. [45] More recently, he proposed, along with the Muwekma Ohlone and Amah Mutsun tribes, restoration of tule elk (Cervus canadensis nannodes) to the San Francisco Peninsula and northern Monterey Bay regions. [46] In 2023, he published, along with California Department of Fish and Wildlife (CDFW) and University of California, Berkeley biologists, a habitat suitability analysis which found long patches of habitat suitable for tule elk from Pacifica to the Pajaro River along the coastal and inland sides of the Santa Cruz Mountains. [47]

Lanman retired from Guardant Health on December 31, 2019, but continued as an Advisor through early 2021. He continues to research and publish in medicine and historical ecology, while also serving on the Boards of Chiara Biosciences, Inc., Circulogene, Inc., WeTree, Inc., and as an Advisor to Forward Health, Inc., Precede Biosciences, Sunbird Bio, Inc., and Teiko Bio, Inc. He was a past Board member of Biolase, Inc. from 2017–2022 and the American Psychiatric Association from 1983–1985. [48] [49]

Representative publications

Journal articles

Book chapters

Personal life

Lanman married Alanna Purcell in 1978 and they raised five sons in Los Altos, California. [55]

See also

Related Research Articles

<span class="mw-page-title-main">Neurology</span> Medical specialty dealing with disorders of the nervous system

Neurology is the branch of medicine dealing with the diagnosis and treatment of all categories of conditions and disease involving the nervous system, which comprises the brain, the spinal cord and the peripheral nerves. Neurological practice relies heavily on the field of neuroscience, the scientific study of the nervous system.

<span class="mw-page-title-main">Low-density lipoprotein</span> One of the five major groups of lipoprotein

Low-density lipoprotein (LDL) is one of the five major groups of lipoprotein that transport all fat molecules around the body in extracellular water. These groups, from least dense to most dense, are chylomicrons, very low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), low-density lipoprotein (LDL) and high-density lipoprotein (HDL). LDL delivers fat molecules to cells. LDL has been associated with the progression of atherosclerosis.

<span class="mw-page-title-main">Biopsy</span> Medical test involving extraction of sample cells or tissues for examination

A biopsy is a medical test commonly performed by a surgeon, an interventional radiologist, or an interventional cardiologist. The process involves the extraction of sample cells or tissues for examination to determine the presence or extent of a disease. The tissue is then fixed, dehydrated, embedded, sectioned, stained and mounted before it is generally examined under a microscope by a pathologist; it may also be analyzed chemically. When an entire lump or suspicious area is removed, the procedure is called an excisional biopsy. An incisional biopsy or core biopsy samples a portion of the abnormal tissue without attempting to remove the entire lesion or tumor. When a sample of tissue or fluid is removed with a needle in such a way that cells are removed without preserving the histological architecture of the tissue cells, the procedure is called a needle aspiration biopsy. Biopsies are most commonly performed for insight into possible cancerous or inflammatory conditions.

<span class="mw-page-title-main">Hypercholesterolemia</span> High levels of cholesterol in the blood

Hypercholesterolemia, also called high cholesterol, is the presence of high levels of cholesterol in the blood. It is a form of hyperlipidemia, hyperlipoproteinemia, and dyslipidemia.

<span class="mw-page-title-main">Cardiac marker</span> Biomarkers relevant to heart function

Cardiac markers are biomarkers measured to evaluate heart function. They can be useful in the early prediction or diagnosis of disease. Although they are often discussed in the context of myocardial infarction, other conditions can lead to an elevation in cardiac marker level.

A tumor marker is a biomarker that can be used to indicate the presence of cancer or the behavior of cancers. They can be found in bodily fluids or tissue. Markers can help with assessing prognosis, surveilling patients after surgical removal of tumors, and even predicting drug-response and monitor therapy.

Biological psychiatry or biopsychiatry is an approach to psychiatry that aims to understand mental disorder in terms of the biological function of the nervous system. It is interdisciplinary in its approach and draws on sciences such as neuroscience, psychopharmacology, biochemistry, genetics, epigenetics and physiology to investigate the biological bases of behavior and psychopathology. Biopsychiatry is the branch of medicine which deals with the study of the biological function of the nervous system in mental disorders.

<span class="mw-page-title-main">John Gofman</span> American scientist

John William Gofman was an American scientist and advocate. He was Professor Emeritus of Molecular and Cell Biology at the University of California at Berkeley.

<span class="mw-page-title-main">Personalized medicine</span> Medical model that tailors medical practices to the individual patient

Personalized medicine, also referred to as precision medicine, is a medical model that separates people into different groups—with medical decisions, practices, interventions and/or products being tailored to the individual patient based on their predicted response or risk of disease. The terms personalized medicine, precision medicine, stratified medicine and P4 medicine are used interchangeably to describe this concept, though some authors and organizations differentiate between these expressions based on particular nuances. P4 is short for "predictive, preventive, personalized and participatory".

In biomedical contexts, a biomarker, or biological marker, is a measurable indicator of some biological state or condition. Biomarkers are often measured and evaluated using blood, urine, or soft tissues to examine normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. Biomarkers are used in many scientific fields.

<span class="mw-page-title-main">Psychiatry</span> Branch of medicine devoted to mental disorders

Psychiatry is the medical specialty devoted to the diagnosis, prevention, and treatment of deleterious mental conditions. These include various matters related to mood, behaviour, cognition, perceptions, and emotions.

Overscreening, also called unnecessary screening, is the performance of medical screening without a medical indication to do so. Screening is a medical test in a healthy person who is showing no symptoms of a disease and is intended to detect a disease so that a person may prepare to respond to it. Screening is indicated in people who have some threshold risk for getting a disease, but is not indicated in people who are unlikely to develop a disease. Overscreening is a type of unnecessary health care.

<span class="mw-page-title-main">J. William Harbour</span> American ophthalmologist and researcher

J. William Harbour is an American ophthalmologist, ocular oncologist and cancer researcher. He is Chair of the Department of Ophthalmology at the University of Texas Southwestern Medical Center in Dallas. He previously served as the vice chair and director of ocular oncology at the Bascom Palmer Eye Institute and associate director for basic science at the Sylvester Comprehensive Cancer Center of the University of Miami's Miller School of Medicine.

Jasvinder K Gambhir is an Indian doctor, researcher and professor in the fields of clinical biochemistry, diabetology and cardiology. Dr Gambhir completed her master's in biochemistry in 1972 from Punjab University and PhD from Post Graduate Institute of Medical Education and Research She has an experience in the field of over 40 years. She is Senior professor and Head of Department, Biochemistry at University College of Medical Sciences, New Delhi and Senior Professor at School of Medical Sciences and Research Noida. Dr. Gambhir is also a member of American Association of Clinical Chemistry (AACC).

Robert Roberts, is a cardiologist, geneticist, academic, and medical researcher.

<span class="mw-page-title-main">Michael Jeffrey Aminoff</span> American clinical neurologist and neurophysiologist

Michael Jeffrey Aminoff is a clinical neurologist and neurophysiologist whose later clinical work focused on treating Parkinson's disease and related movement disorders. He retired in 2022 and lives in San Francisco, California.

<span class="mw-page-title-main">Lee Goldman</span> American cardiologist and educator

Lee Goldman is an American cardiologist and educator at Columbia University, where he is professor of medicine at the Vagelos College of Physicians and Surgeons, professor of epidemiology at the Mailman School of Public Health, and dean emeritus of the Faculties of Health Sciences and Medicine. From 2006 to 2020 he served as executive vice president and dean of the Faculties of Health Sciences and Medicine, chief executive officer of the Columbia University Irving Medical Center, and Harold and Margaret Hatch Professor of the university. Before moving to Columbia, he was chair of the department of medicine at the University of California, San Francisco. He received his B.A., M.D., and M.P.H. degrees from Yale University.

<span class="mw-page-title-main">Helmy Eltoukhy</span> American scientist and entrepreneur

Helmy Eltoukhy is an American scientist and a businessperson who co-founded startups Avantome and Guardant Health. He is best known for his contributions to genomics, semiconductor DNA sequencing, and personalized medicine. His startups were acquired by Illumina in 2008. Avantome was founded to develop and commercialize semiconductor-based DNA sequencing, during the race for the $1,000 genome. Guardant Health was founded to pioneer non-invasive liquid biopsy approaches for cancer diagnosis, monitoring, personalized medicine treatment, and research.

Michelle Asha Albert is an American physician who is the Walter A. Haas Lucie-Stern Endowed Chair in Cardiology and professor of medicine at the University of California, San Francisco. Albert is director of the UCSF Center for the Study of Adversity and Cardiovascular Disease. She is president of the American Heart Association. She served as the president of the Association of Black Cardiologists in 2020–2022 and as president of the Association of University Cardiologists (2021–2022). Albert is an elected member of the National Academy of Medicine, the American Society of Clinical Investigators and the Association of American Physicians.

<span class="mw-page-title-main">Guardant Health</span> American biotechnology company

Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.

References

  1. 1 2 Ben Goldfarb (2018). Eager: The Surprising, Secret Life of Beavers and Why They Matter. Chelsea Green Publishing. pp. 135–141. ISBN   9781603587402 . Retrieved January 6, 2019.
  2. 1 2 L. Page (May 15, 2000). "Fee for Episode". American Medical News. pp. 13–14.
  3. 1 2 3 Lanman R (1994). Horn SD; Hopkins DSP (eds.). Improving Pediatric Asthma Care in a Health Maintenance Organization, in Clinical Practice Improvement: A New Technology for Developing Cost-Effective Quality Health Care. New York: Faulkner & Gray, Inc. pp. 169–174. ISBN   9781881393252.
  4. 1 2 João Medeiros (February 5, 2017). "Marcus Krause's lung cancer wouldn't stop growing. Then he took a new kind of blood test". Wired UK. Retrieved February 1, 2020.
  5. ↑ Richard Harris (December 16, 2016). "When Genetic Tests Disagree About Best Option For Cancer Treatment". National Public Radio (NPR). Retrieved February 3, 2020.
  6. 1 2 Anna Czene (December 11, 2019). "Study Shows Only 40 Percent of Patients with Metastatic Colon Cancer Receive Guideline-Recommended Biomarker Testing". Barron's. Retrieved February 20, 2020.
  7. ↑ "PubMed Single Citation Matcher". National Library of Medicine National Center for Biotechnology Information. Retrieved April 14, 2022.
  8. ↑ Robert Bauver (2017). "Memories of Marti: In Memoriam" (PDF). ATADA News. Antique Tribal Art Dealer Association. pp. 8–9. Retrieved January 27, 2018.
  9. ↑ Ogunro EA; Lanman RB; Spencer JR; Ferguson AG; Lesch M (November 1979). "Degradation of canine cardiac myosin and actin by cathepsin D isolated from homologous tissue". Cardiovasc Research. 13 (11): 621–629. doi:10.1093/cvr/13.11.621. PMID   42492.
  10. ↑ H. Levenson; R. Lanman; M. Rankin (1982). "Traumatic war neurosis and phenelzine". Archives of General Psychiatry. 39 (11): 1345. doi:10.1001/archpsyc.1982.04290110093018. PMID   7138237.
  11. 1 2 Lanman RB; Pardes H; Benedek EP; Rink PJ; Wiener JM (1989). Talbott JA (ed.). Reorganizing for the Future, in Future Directions for Psychiatry. Washington, D.C.: American Psychiatric Press, Inc. pp. 172–180. ISBN   9780890422151.
  12. ↑ "From Kaiser to San Jose". San Francisco Business Times. October 4, 1993. p. 19.
  13. ↑ Physician-Driven Integration: A response to the Corporatization of Medicine (PDF) (Report). Philadelphia, Pennsylvania: American College of Physicians. 1996. S2CID   38844951. Archived from the original (PDF) on 2019-02-23.
  14. ↑ James C. Robinson; Lawrence P. Casalino (December 21, 1995). "The Growth of Medical Groups Paid through Capitation in California". New England Journal of Medicine. 333 (25): 1684–1687. doi: 10.1056/NEJM199512213332506 . PMID   7477222.
  15. ↑ Capitation in California: A Study of Physician Organizations Managing Risk. Maurice Penner. 1997. p. 44. ISBN   978-1-56793-051-1.
  16. ↑ Philip M. Mack (July 1, 1996). "A Capital Idea". California Medicine. Vol. 3, no. 7. San Francisco, California: California Medicine Publishing, Inc. pp. R3–R14.
  17. ↑ Wendy Sheanin (August 8, 1995). "People in Business". SFGate/San Francisco Chronicle.
  18. ↑ Peter Sinton (February 11, 1998). "Venture Money Pot Swells / Information technology firms draw bulk of it". San Francisco Chronicle.
  19. ↑ Chris Rauber (December 17, 1995). "Medical services firm to assist specialists' operations". San Francisco Business Times. p. 9.
  20. ↑ Jeff Goldsmith (December 2000). "The Internet And Managed Care: A New Wave Of Innovation". Health Affairs. 19 (6): 42–56. doi:10.1377/hlthaff.19.6.42. PMID   11192421.
  21. ↑ Chris Rauber (August 10, 1997). "Adesso looks toward national expansion". San Francisco Business Times.
  22. ↑ Vanessa Gisquet (September 30, 2004). "Blood Feud". Forbes. Retrieved February 6, 2020.
  23. ↑ Anne Paxton (July 1, 2002). "One option for a more complete profile". CAP Today. Retrieved February 2, 2020.
  24. ↑ Krishnaji R. Kulkarni (December 2006). "Cholesterol profile measurement by vertical auto profile method". Clinics in Laboratory Medicine. 26 (4): 787–802. doi:10.1016/j.cll.2006.07.004. PMID   17110240.
  25. ↑ Joshi PH; Khokhar AA; Massaro JM; Lirette ST; Griswold ME; Martin SS; Blaha MJ; Kulkarni KR; Correa A; D'Agostino RB Sr.; Jones SR; Toth PP (April 2016). "Remnant lipoprotein cholesterol and incident coronary heart disease: The Jackson Heart and Framingham Offspring Cohort Studies". Journal of the American Heart Association. 5 (5): 1–10. doi:10.1161/JAHA.115.002765. PMC   4889167 . PMID   27130348.
  26. ↑ Paul T. Williams; Xue-Qiao Zhao; Santica M.; Marcovina, James D.; Otvos, B.; Greg Brown; Ronald M. Krauss (April 2014). "Comparison of four methods of analysis of lipoprotein particle subfractions for their association with angiographic progression of coronary artery disease". Atherosclerosis. 233 (2): 713–720. doi:10.1016/j.atherosclerosis.2014.01.034. PMC   3990359 . PMID   24603218.
  27. ↑ R. B. Lanman (2004). "VAP - A Better Cholesterol Test". Journal of Clinical Ligand Assay. 27: 97–100.
  28. ↑ Ben Piper (January 13, 2011). "Atherotech acquired by Behrman Capital". Birmingham Business Journal. Retrieved January 31, 2020.
  29. ↑ Karen Lusky (July 2008). "New clue for predicting stroke risk: Lp-PLA2". CAP Today.
  30. ↑ FDA Decision Summary: 510(k) Substantial Equivalent Determination (PDF) (Report). December 15, 2005.
  31. ↑ Thompson A; Gao P; Orfei L; Watson S; Di Angelantonio E; Kaptoge S; Gao P; Orfei L; Watson S; Di Angelantonio E; Kaptoge S; Ballantyne C; Cannon CP; Criqui M; Cushman M; Hofman A; Packard C; Thompson SG; Collins R; Danesh J (May 2010). "Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies". Lancet. 375 (9725): 1536–44. doi:10.1016/S0140-6736(10)60319-4. PMC   2864403 . PMID   20435228.
  32. ↑ "VaxGen to Acquire diaDexus in a Stock-for-Stock Merger". FierceBiotech. April 14, 2010.
  33. ↑ "Veracyte, Inc. developed diagnostics for thyroid and non-small cell lung cancer". iCloudNewswire. July 4, 2019.
  34. 1 2 E. K. Alexander; G. C. Kennedy; Z. W. Baloch; E. S. Cibas; D. Chudova; J. Diggans; L. Friedman; R. T. Kloos; V. A. LiVolsi; S. J. Mandel; S. S. Raab; J. Rosai; D. L. Steward; P. S. Walsh; J. I. Wilde; M. A. Zeiger; R. B. Lanman; B. R. Haugen (August 23, 2012). "Preoperative diagnosis of benign thyroid nodules with indeterminate cytology". New England Journal of Medicine. 367 (8): 705–715. doi: 10.1056/NEJMoa1203208 . PMID   22731672. S2CID   4992970.
  35. ↑ "New tissue test for idiopathic pulmonary fibrosis changes the diagnostic game". PulmCCM. December 6, 2019.
  36. ↑ Mark Hollmer (October 13, 2013). "Veracyte goes public, raises $65M and gains on Day 1". FierceBiotech.
  37. ↑ "Guardant Health Liquid Biopsy Test Gets Expanded Medicare Coverage for Solid Tumors". GenomeWeb. December 19, 2019.
  38. ↑ Emma Court (October 14, 2018). "Guardant Health IPO: 5 things to know about the startup that wants to detect cancer early". MarketWatch.
  39. ↑ Sue Dremanna (Apr 7, 2023). "Inside one man's hunt to rediscover lost animal species". Palo Alto Weekly. Palo Alto, California. Retrieved June 6, 2024.
  40. ↑ Rick Lanman (Summer 2021). "Once Upon a Time Los Altans Fly Fished Adobe Creek". Under the Oaks. Los Altos, California: Los Altos Historical Museum. Retrieved June 6, 2024.
  41. 1 2 Lanman RB; Perryman H; Dolman B; James CD (2012). "The historical range of beaver in the Sierra Nevada: a review of the evidence". California Fish and Game. 98 (2): 65–80. Retrieved January 6, 2019.
  42. ↑ Lanman RB; Perryman H; Dolman B; James CD (2012). "The historical range of beaver in the Sierra Nevada: a review of the evidence". California Fish and Game. 98 (2): 65–80. Retrieved January 6, 2019.
  43. ↑ Lanman CW; Lundquist K; Perryman H; Asarian JE; Dolman B.; Lanman RB; Pollock MM (2013). "The historical range of beaver (Castor canadensis) in coastal California: an updated review of the evidence". California Fish and Game. 99 (4): 193–221. Retrieved January 6, 2019.
  44. ↑ Leigh Marymor; Richard Burnham Lanman (2021). "Western Message Petroglyphs indicate historic beaver presence in a San Francisco Bay Area watershed". California Fish and Wildlife Journal. 107 (2): 89–98. doi: 10.51492/cfwj.107.8 . Retrieved June 6, 2024.
  45. 1 2 R. B. Lanman; L. Hylkema; C. M. Boone; B. Allée; R. O. Castillo; S. A. Moreno; M. F. Flores; U. DeSilva; B. Bingham; B. M. Kemp (2021). "Ancient DNA analysis of archaeological specimens extends Chinook salmon's known historic range to San Francisco Bay's tributaries and southernmost watershed". PLOS ONE. 16 (4): e0244470. Bibcode:2021PLoSO..1644470L. doi: 10.1371/journal.pone.0244470 . PMC   8049268 . PMID   33857143.
  46. 1 2 Richard B. Lanman; William C. Leikam; Monica V. Arellano; Alan Leventhal; Valentin Lopez; Ryan A. Phillips; Julie A. Phillips; Kristin Denryter (October 12, 2022). "Review of considerations for restoration of tule elk (Cervus canadensis nannodes) to the San Francisco Peninsula and northern Monterey Bay counties of California". California Fish and Wildlife Journal. 108 (3). doi: 10.51492/cfwj.108.14 . Retrieved October 23, 2022.
  47. ↑ T. Connor; T. J. Batter; C. O. Langer; J. Cann; C. McColl; R. B. Lanman (2023). "Habitat suitability assessment for tule elk in the San Francisco Bay and Monterey Bay areas". California Fish and Wildlife Journal. 109: e19. doi: 10.51492/cfwj.109.19 . Retrieved June 6, 2024.
  48. ↑ "BIOLASE Appoints Richard B. Lanman to Board of Directors". Biolase, Inc. October 31, 2017. Retrieved October 23, 2022.
  49. ↑ "American Psychiatric Association Board Election". Psychiatric News. Washington, D.C.: American Psychiatric Association Publishing. January 18, 1985. Retrieved October 23, 2022.
  50. ↑ R. B. Lanman; R. L. Wolfert; J. K. Fleming; A. S. Jaffe; W. L. Roberts; G. R. Warnick; J. P. McConnell (2006). "Lipoprotein-associated phospholipase A2: review and recommendation of a clinical cut point for adults". Preventive Cardiology. 9 (3): 138–143. doi: 10.1111/j.1520-037X.2006.05547.x . PMID   16849876.
  51. ↑ J. B. Muhlestein; H. T. May; J. R. Jensen; B. D. Horne; R. B. Lanman; F. Lavasani; R. L. Wolfert; R. R. Pearson; H. D. Yannicelli; J. L. Anderson (July 18, 2006). "The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study". Journal of the American College of Cardiology. 48 (2): 396–401. doi:10.1016/j.jacc.2006.05.009. PMID   16843192.
  52. ↑ Lanman, Richard B.; Mortimer, Stefanie A.; Zill, Oliver A.; Sebisanovic, Dragan; Lope, Rene; Blau, Sibel; Collisson, Eric A.; Divers, Stephen G; Hoon, Dave S. B.; Kopetz, E. Scott; Lee, Jeeyun; Nikolinakos, Petros G.; Baca, Arthur M.; Kermani, Bahram G.; Eltoukhy, Helmy; Talasaz, AmirAli (16 Oct 2015). "Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA". PLOS One . 10 (10): e0140712. Bibcode:2015PLoSO..1040712L. doi: 10.1371/journal.pone.0140712 . PMC   4608804 . PMID   26474073.
  53. ↑ C. M. Blakely; T. B. K. Watkins; W. Wu; B. Gini; J. J. Chabon; C. E. McCoach; N. McGranahan; G. A. Wilson; N. J. Birkbak; V. R. Olivas; J. Rotow; A. Maynard; V. Wang; M. A. Gubens; K. C. Banks; R. B. Lanman; A. F. Caulin; J. St John; A. R. Cordero; P. Giannikopoulos; A. D. Simmons; P. C. Mack; D. R. Gandara; H. Husain; R. C. Doebele; J. W. Riess; M. Diehn; C. Swanton; T. G. Bivona (November 6, 2017). "Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers". Nature Genetics. 49 (12): 1693–1704. doi:10.1038/ng.3990. PMC   5709185 . PMID   29106415.
  54. ↑ T. P. Slavin; K. C. Banks; D. Chudova; G. R. Oxnard; J. I. Odegaard; R. J. Nagy; K. W. K. Tsang; S. L. Neuhausen; S. W. Gray; M. Cristofanilli; A. A. Rodriguez; A. Bardia; B. Leyland-Jones; M. F. Janicek; M. Lilly; G. Sonpavde; C. E. Lee; R. B. Lanman; F. Meric-Bernstam; R. Kurzrock; J. N. Weitzel (December 10, 2018). "Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing". Journal of Clinical Oncology. 36 (35): 3459–3465. doi:10.1200/JCO.18.00328. PMC   6286162 . PMID   30339520.
  55. ↑ Carolyn Barnes (December 23, 1998). "Family frolic". Los Altos Town Crier. Retrieved April 12, 2022.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.